Advertisement

Topics

FDA Panel Backs Liraglutide to Reduce CV Risk Factors

11:20 EDT 21 Jun 2017 | Medscape

UPDATED // An FDA panel recommended liraglutide for the additional indication of reducing the risk for major adverse cardiovascular events in adults with type 2 diabetes and high cardiovascular risk.
Medscape Medical News

Original Article: FDA Panel Backs Liraglutide to Reduce CV Risk Factors

NEXT ARTICLE

More From BioPortfolio on "FDA Panel Backs Liraglutide to Reduce CV Risk Factors"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...